Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
KardiganKARD +3.13%11 Market Cap is $1,830.58 Mil as of Aug. 04, 2026. GuruFocus rates KARD with a GF Score™ of 11/100. The stock has 1 warning sign investors should review. Among 1,423 Biotechnology companies, Kardigan ranks better than 86.93% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Kardigan's share price for the quarter that ended in Dec. 2025 was $0. Kardigan's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 89.34 Mil. Therefore, Kardigan's market cap for the quarter that ended in Dec. 2025 was $0.00 Mil.
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Kardigan's Enterprise Value for Today is $1,557.39 Mil.
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Kardigan Market Cap Related Terms
Kardigan Market Cap Historical Data
* Premium members only.
The historical data trend for Kardigan's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kardigan Market Cap Chart
Kardigan Annual Data
Trend
Dec24
Dec25
Market Cap
0.00
0.00
Kardigan Semi-Annual Data
Dec24
Dec25
Market Cap
0.00
0.00
KARD vs OCUL, GHRS, FTRE: Market Cap Comparison
For the Biotechnology subindustry, Kardigan's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kardigan Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kardigan's Market Cap distribution charts can be found below:
* The bar in red indicates where Kardigan's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Kardigan's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kardigan (KARD) has a Market Cap of $1,830.58 Mil as of Aug. 04, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Kardigan and its competitors. According to the industry distribution chart, Kardigan ranks #186 out of 1423 companies in the Biotechnology industry, placing it in the top 13.1%.
Is Kardigan's Market Cap too high?
Kardigan's current Market Cap is $1,830.58 Mil. The Biotechnology industry median Market Cap is 114.69. Kardigan's value of $1,830.58 Mil is 1496.1% above this industry median. Based on the distribution chart, Kardigan ranks #186 out of 1423 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Kardigan has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Kardigan's Market Cap compare to OCUL and GHRS?
According to the Biotechnology industry distribution chart, Kardigan ranks #186 out of 1423 companies for Market Cap. This places Kardigan in the top 13% of its industry — outperforming the majority of peers. The industry median Market Cap is 114.69. Kardigan's value of $1,830.58 Mil is 1496.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 114.69, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kardigan's current Market Cap of $1,830.58 Mil is 1496.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Kardigan and its competitors. For the Biotechnology industry, the median Market Cap is 114.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kardigan's current Market Cap is $1,830.58 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kardigan stock overvalued right now?
Kardigan (KARD) has a current Market Cap of $1,830.58 Mil. The current Market Cap is $1,830.58 Mil and 1496.1% above the Biotechnology industry median of 114.69. Kardigan's overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Kardigan (KARD), the current Market Cap is $1,830.58 Mil as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.
11GF Score
Get the complete analysis for KARD
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KARD has been successfully added to your 
